Archives
-
PP 1: Src Family Kinase Assay Workflows
2026-08-14
Turn PP 1 into a practical pathway-dissection tool for Lck, Fyn, Lyn, and RET-driven signaling. This guide combines assay design, concentration planning, orthogonal validation, and troubleshooting for cancer and immunology workflows.
-
AZD0156: Reading ATM Inhibition in Cancer
2026-08-13
AZD0156 is a selective ATM kinase inhibitor for dissecting DNA damage signaling, repair, and metabolic adaptation. This article translates evidence from high-grade serous ovarian cancer research into a phenotype-centered assay strategy for cancer therapy research.
-
Bsa I (RNase-free): Workflow Guide
2026-08-13
Bsa I (RNase-free) provides sequence-specific DNA cleavage for cloning and other molecular biology research workflows where RNA integrity must also be protected. It is intended for research use only, not diagnostic or medical applications, and should be used with validated reaction conditions and appropriate RNase-control practices.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-12
The reference study developed a nonviral tumor suppressor replacement strategy in which chemically modified CDKN1A/p21 mRNA was packaged in lipid nanoparticles for intravesical delivery. Across molecular, cellular, biodistribution, and orthotopic mouse experiments, the approach restored nuclear p21 expression, inhibited bladder tumor growth, and limited systemic exposure, while remaining subject to important preclinical and formulation-specific limitations.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-12
Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for examining KIT, PDGFRα, and PDGFRβ signaling in cancer, mast cell, and inflammatory models. It is appropriate for targeted in vitro workflows but should not be used where aqueous or ethanol solubility, broad-spectrum kinase inhibition, or clinical treatment guidance is required.
-
Phenothiazines Boost Macrophage Antibacterial Activity
2026-08-11
The 2025 Frontiers in Immunology study shows that phenothiazines, including perphenazine, strengthen macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. Inhibitor and scavenger experiments support a host-directed mechanism, while an in vivo Salmonella Typhimurium model indicates reduced tissue injury and inflammation.
-
Alternariol (AOH) Research Workflows
2026-08-11
Build reproducible AOH experiments that connect mycotoxin exposure with CYP metabolism, apoptosis, cytoskeletal injury, and hepatic stellate-cell activation. This practical guide combines compound handling, dose-finding, fibrosis endpoints, and CotA-oriented detoxification comparisons.
-
Perospirone: Receptor and Kv1.5 Pharmacology
2026-08-10
Perospirone, also called SM-9018 free base, combines high-affinity 5-HT2A and D2 receptor antagonism with partial 5-HT1A agonism. Recent ex vivo evidence adds concentration-dependent inhibition of vascular Kv currents, supporting a broader framework for schizophrenia research and cardiovascular safety studies.
-
HDAC Inhibitors and NUT Carcinoma Transcription
2026-08-09
Shiota et al. developed a dCAS9-based GFP reporter screen to identify chemical repressors of NUT transcriptional activity. The study shows that panobinostat and the structurally distinct compound IRBM6 disrupt BRD4-NUT megadomain function, suppress oncogenic transcription, promote differentiation, and inhibit NUT carcinoma growth in cellular and xenograft models.
-
Olsalazine Sodium Workflows for Inflammation Research
2026-08-08
Olsalazine Sodium connects LTB4-focused macrophage assays with colorectal cancer and xenobiotic-clearance workflows. This guide emphasizes aqueous formulation, structure-aware controls, transporter-expression readouts, and practical troubleshooting for reproducible research use.
-
Olsalazine Sodium: Designing Better Cancer Assays
2026-08-07
Olsalazine Sodium is a mesalamine dimer and anti-inflammatory prodrug with value in colorectal cancer tumor models. This article explains how to connect LTB4 chemotaxis, tumor apoptosis induction, compound handling, and transporter-aware assay design without overinterpreting cross-domain evidence.
-
AZD0156: Strategic ATM Kinase Inhibition for Translational I
2026-08-07
Explore the mechanistic basis and translational promise of AZD0156, a potent and selective ATM kinase inhibitor, in redefining cancer therapy research. This article bridges foundational insights in DNA damage response with actionable guidance for translational researchers, highlighting combinatorial strategies and metabolic vulnerabilities, and situates AZD0156 within the evolving competitive and clinical landscape.
-
Acetylspiramycin: Bench Protocols for Antimicrobial Resistan
2026-08-06
Acetylspiramycin (Spiramycin B) stands out for its potent activity against resistant Gram-positive and atypical pathogens, and its immune-modulating roles. This guide translates cutting-edge resistance findings and validated workflows into actionable protocols for researchers tackling evolving clinical threats.
-
Tubastatin A and HDAC6: Redefining Translational Horizons
2026-08-06
This thought-leadership article provides a mechanistic and strategic perspective on Tubastatin A, a selective HDAC6 inhibitor, for translational researchers. Integrating recent preclinical findings, competitive context, and actionable workflow guidance, the piece positions Tubastatin A as a transformative tool in cardiovascular, cancer, and neuroprotective research, with particular emphasis on its role in modulating cell death pathways and inflammation.
-
Liproxstatin-1: Precision Ferroptosis Inhibition in Sex-Bias
2026-08-05
Explore how Liproxstatin-1, a leading ferroptosis inhibitor, enables rigorous, sex-specific modeling of ferroptotic cell death. This article uniquely bridges biochemical characterization with cutting-edge insights from recent studies on oxidative stress and salivary dysfunction.